Drug Trial Radar · NCT03165240
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Oct 5, 2017
Primary completion
Apr 16, 2020
Study completion May 7, 2020
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor \[ACEi\] or Angiotensin-receptor blockers \[ARB\]. Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine Ratio \[UACR\].
Conditions
- Diabetic Nephropathies
Interventions
BI 690517Drug
Film-coated tablet
EplerenoneDrug
Film-coated tablet
PlaceboDrug
Film-coated tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with drug related Adverse Events (AEs)Time frame: Up to 35 days
Locations
40 sites in 10 countries. Site status is shown where the registry gives one.
Steno Diabetes Center Copenhagen
Gentofte Municipality, Denmark
Bispebjerg og Frederiksberg Hospital
København NV, Denmark
Copenhagen University Hospital, Rigshospitalet
København Ø, Denmark
Kolding Sygehus
Kolding, Denmark
HOP d'Angers
Angers, France
HOP Michallon
La Tronche, France
HOP Bichat
Paris, France
HOP la Milétrie
Poitiers, France
HOP Nord Laënnec
Saint-Herblain, France
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
InnoDiab Forschung GmbH
Essen, Germany
Inamed GmbH
Gauting, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany
Univ. Gen. Hosp. of Ioannina
Ioannina, Greece
Iatriko of Athens Group/ Iatriko of P. Faliro
P. Faliro, Greece
Iatriko Psychikou
Psychikó, Greece
University General Hospital of Thessaloniki AHEPA
Thessaloniki, Greece
Hospital Dr. Nélio Mendonça
Funchal, Portugal
APDP - Associação Protectora dos Diabéticos de Portugal
Lisbon, Portugal
CHULN, EPE - Hospital de Santa Maria
Lisbon, Portugal
Hospital Beatriz Ângelo
Loures, Portugal
Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António
Porto, Portugal
Res.Inst.-Compl.Iss.Cardi.Dis.
Kemerovo, Russia
City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow
Moscow, Russia
Nonstate Private Healthcare Institution "Scientific Clinical Center of LLC Russian Railways"
Moscow, Russia
Baltic Med,LLC Clinic BaltMed Ozerki
Saint Petersburg, Russia
D & R s.r.o.
Košice, Slovakia
Hospital A Coruña
A Coruña, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Puerta de Hierro
Majadahonda, Spain
Hospital Virgen Macarena
Seville, Spain
Hospital Clínico de Valencia
Valencia, Spain
CTC Sahlgrenska Universitetssjukhuset
Gothenburg, Sweden
Sjukhuset, Härnösand
Härnösand, Sweden
Universitetssjukhuset, Örebro
Örebro, Sweden
CTC Clinical Trial Consultants AB
Uppsala, Sweden
University Hospital of Wales
Cardiff, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.